UroGen Pharma announced strong preliminary results from its Phase 3 UTOPIA trial for UGN-103, showing a 77.8% three-month complete response rate for patients with recurrent low-grade intermediate-risk ...

Muscle-invasive bladder cancer management is challenging for cisplatin-ineligible patients due to limited treatment options and high recurrence rates. The Padcev-Keytruda combination therapy ...

Throughout October, CURE highlighted research developments and evolving treatment strategies that continue to shape cancer ...

The robust 77.8% three-month CR rate observed in the UTOPIA trial is highly encouraging and reinforces the potential of UGN-103 to deliver meaningful benefits to patients,” said Liz Barrett, President ...

Reported three-month complete response rate of 77.8% from the Phase 3 UTOPIA trial of UGN-103, consistent with ENVISION results; FDA agreed to ...

Despite majoring in engineering, a Cranberry Township woman took on a health-related project when applying to graduate school ...

The FMI report, “Bladder Liners Market Size, Share, and Forecast 2025–2035,” projects global revenues to increase by USD 1.18 ...

If you're an individual retail investor searching for healthcare stocks you can buy and hold for at least 20 years, here are ...

Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 134.1 million in the third quarter of 2025 (Q3 2024: NOK 120.1 million), and an EBITDA of NOK 10.2 million (Q3 2024: NOK 5.0 ...

The reactive tire bladder release agent market is projected to grow steadily as manufacturers prioritize production ...

Merck (NYSE:MRK) announced on Thursday that the FDA has granted priority review for two of its marketing applications aimed at expanding the U.S. indications of injectable and intravenous versions of ...

The hospital is the first in Baton Rouge to offer Aquablation therapy with an AI-powered robotic system to treat benign prostatic hyperplasia (BPH), a condition that affects about half of men over the ...